NOTTINGHAM, England, March 14, 2023 /PRNewswire/ -- Albumedix Ltd ('Albumedix'), Nottingham, United Kingdom, now part of the global life science group Sartorius, and Heartseed Inc ('Heartseed'), Tokyo, Japan, Tuesday 14th March 2023, announce that Recombumin® is a critical component of Heartseed's HS-001, an investigational cardiac remuscularization cell therapy which has commenced first in human dosing.
Read more at prnewswire.comAlbumedix and Heartseed announce Recombumin® as a critical excipient in the manufacture of Heartseed's HS-001 investigational cell therapy as its first in-human trial commences
PR Newswire - Press Release 
All information and data in this article is solely for informational purposes. For more information please view the Barchart Disclosure Policy here
/Netflix%20on%20tv%20with%20remote%20by%20freestocks%20via%20Unsplash.jpg)
/AI%20(artificial%20intelligence)/Ai%20chip%20by%20Quality%20Stock%20Arts%20via%20Shutterstock.jpg)
/A%20Palantir%20office%20building%20in%20Tokyo_%20Image%20by%20Hiroshi-Mori-Stock%20via%20Shutterstock_.jpg)
/Semiconductor%20Chip%20by%20Gorodenkoff%20via%20Shutterstock.jpg)
/Micron%20Technology%20Inc_billboard-by%20Poetra_RH%20via%20Shutterstock.jpg)